A carregar...
Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
OBJECTIVE: To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2−) advanced breast cancer from a UK payer perspective. METHODS: A cohort-base...
Na minha lista:
| Publicado no: | J Health Econ Outcomes Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Columbia Data Analytics, LLC
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7299496/ https://ncbi.nlm.nih.gov/pubmed/32685577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/9725 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|